Cite
MLA Citation
B.C. Cho et al.. “Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC).” European journal of cancer, vol. 174, n.d., pp. S1–S2. http://access.bl.uk/ark:/81055/vdc_100168600225.0x000042